Wednesday, May 8, 2013

Takeda to Acquire Vaccine development company - Inviragen Inc

Takeda Pharmaceutical Company Limited will acquire privately held  Inviragen which is focused into research and development of innovative vaccines for emerging infectious diseases, including dengue and hand, foot and mouth disease.

Takeda will pay an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.
Inviragen lead vaccine candidate is DENVax which is a four-strain recombinant viral vaccine for the prevention of dengue infection. An administration schedule of two doses of DENVax over 90 days is currently being evaluated in Phase 2 clinical trials. In addition to DENVax, Inviragen’s pipeline contains a vaccine candidate to protect against hand, foot and mouth disease (HFMD) caused by enterovirus 71 (EV71), which has completed Phase 1 clinical testing. Inviragen has also developed a recombinant vaccine candidate to protect against chikungunya, currently in preclinical development.